The DOI matches its Crossref record.
PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells
Open accessAbstract
Progress in the treatment of solid tumors has been slow and sporadic. The efficacy of conventional chemotherapy in solid tumors is limited because tumors frequently have mutations in the p53 gene. Also, chemotherapy only kills rapidly dividing cells. Members of the tumor necrosis factor (TNF) family, however, induce apoptosis regardless of the p53 phenotype. Unfortunately, the cytotoxicity of TNF-alpha is limited by its activation of NF-kappaB and activation of NF-kappaB is proinflammatory. We have identified a compound called PG490, that is composed of purified triptolide, which induces apoptosis in tumor cells and sensitizes tumor cells to TNF-alpha-induced apoptosis. PG490 potently inhibited TNF-alpha-induced activation of NF-kappaB. PG490 also blocked TNF-alpha-mediated induction of c-IAP2 (hiap-1) and c-IAP1 (hiap-2), members of the inhibitor of apoptosis (IAP) family. Interestingly, PG490 did not block DNA binding of NF-kappaB, but it blocked transactivation of NF-kappaB. Our identification of a compound that blocks TNF-alpha-induced activation of NF-kappaB may enhance the cytotoxicity of TNF-alpha on tumors in vivo and limit its proinflammatory effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility
van Horssen, R., ten Hagen, T. L. M., & Eggermont, A. M. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-397 · Cited by 701
Arylglyoxals in Synthesis of Heterocyclic Compounds
Eftekhari-Sis, B., Zirak, M., & Akbari, A. (2013) · Chemical Reviews · doi:10.1021/cr300176g · Cited by 453
Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae)
Brinker, A. M., Ma, J., Lipsky, P. E., & Raskin, I. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2006.11.029 · Cited by 415
Triptolide: Progress on research in pharmacodynamics and toxicology
Li, X.-J., Jiang, Z.-Z., & Zhang, L.-Y. (2014) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.06.006 · Cited by 378
“Combining TP with TNF-α improved anti-tumor activity by inhibiting NF-κB, which is the primary cause of its side effects (Lee et al., 1999).”
BackgroundTriptolide and its expanding multiple pharmacological functions
Liu, Q. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.012 · Cited by 345
Chen, S.-R., Dai, Y., Zhao, J., Lin, L., Wang, Y., & Wang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00104 · Cited by 326
Inhibitors of the heat shock response: Biology and pharmacology
Powers, M. V., & Workman, P. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.05.040 · Cited by 320
Zhou, Z.-L., Yang, Y.-X., Ding, J., Li, Y.-C., & Miao, Z.-H. (2012) · Natural Product Reports · doi:10.1039/c2np00088a · Cited by 312
Qiu, D., & Kao, P. N. (2003) · Drugs in R & D · doi:10.2165/00126839-200304010-00001 · Cited by 311
“tional activation without inhibiting nuclear NF-κB DNA-binding activity.[58,63] Recent studies have revealed that NF-κB transcriptional activation is regulated in the nucleus by variable interactions between co-repressor histone deacetylases and coactivating acetyltransferases.”
BackgroundInfluentialSelf-citationTumor necrosis factor, cancer and anticancer therapy
MOCELLIN, S., ROSSI, C., PILATI, P., & NITTI, D. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.11.001 · Cited by 311
Chen, B. J. (2001) · Leukemia & Lymphoma · doi:10.3109/10428190109064582 · Cited by 301
Chen, P., Li, J., Barnes, J., Kokkonen, G. C., Lee, J. C., & Liu, Y. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.11.6408 · Cited by 286
Lee, H., Kim, Y. O., Kim, H., Kim, S. Y., Noh, H. S., Kang, S. S., Cho, G. J., Choi, W. S., & Suk, K. (2003) · The FASEB Journal · doi:10.1096/fj.03-0057fje · Cited by 278
Qiu, D., Zhao, G., Aoki, Y., Shi, L., Uyei, A., Nazarian, S., Ng, J. C.-H., & Kao, P. N. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13443 · Cited by 269
Self-citationThe role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies
Schwartz, S. A., Hernandez, A., & Mark Evers, B. (1999) · Surgical Oncology · doi:10.1016/s0960-7404(00)00012-8 · Cited by 132
Kitzen, J. J. E. M., de Jonge, M. J. A., Lamers, C. H. J., Eskens, F. A. L. M., van der Biessen, D., van Doorn, L., ter Steeg, J., Brandely, M., Puozzo, C., & Verweij, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.026 · Cited by 89
Kim, S.-H., Kim, D.-H., Lavender, P., Seo, J.-H., Kim, Y.-S., Park, J.-S., Kwak, S.-J., & Jee, Y.-K. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.5.033 · Cited by 34
Metadata
- Authors
- Lee, K. Y., Chang, W.-T., Qiu, D., Kao, P. N., & Rosen, G. D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 274
- Issue
- 19
- Pages
- 13451-13455
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1969791237
- Cited by
- 184
- References
- 0
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.